Snapshot from May 31, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / GlucaPharm Inc.
Entity

GlucaPharm Inc.

Tracked across 1 events · 7 articles · First seen May 12, 2026 · Last active May 14, 2026

Sentiment
60
Attention
4
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
4 60
Tech
SureNano Science develops GLP-1 GEP-44
SureNano Science, through its subsidiary GlucaPharm Inc., is developing a next-generation GLP-1 platform centered on GEP-44, a novel triple agonist peptide. This peptide is engineered to improve efficacy, tolerability, and delivery flexibility for treating obesity…
Impact: GlucaPharm Inc., a subsidiary of SureNano Science, is the developer of the GEP-44 peptide, a key asset in SureNano Science's GLP-1 platform.
May 12, 2026 · 7 articles
Key Actions (1)
80 SureNano Science acquired GlucaPharm Inc.SureNano Science develops...
NEWSDESK
Track GlucaPharm Inc. live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.